 Brian Montague
Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prisoners | 10 | 2020 | 128 | 2.550 |
Why?
| | Prisons | 8 | 2020 | 74 | 1.860 |
Why?
| | Emergency Responders | 2 | 2022 | 34 | 1.670 |
Why?
| | HIV Infections | 20 | 2020 | 2459 | 1.620 |
Why?
| | Immunoglobulin A | 2 | 2022 | 174 | 0.960 |
Why?
| | Asymptomatic Infections | 1 | 2022 | 23 | 0.830 |
Why?
| | Antibodies, Viral | 2 | 2022 | 542 | 0.820 |
Why?
| | Viral Load | 3 | 2018 | 419 | 0.820 |
Why?
| | Patient Acceptance of Health Care | 3 | 2018 | 687 | 0.750 |
Why?
| | Continuity of Patient Care | 3 | 2018 | 265 | 0.710 |
Why?
| | Rhode Island | 10 | 2018 | 23 | 0.710 |
Why?
| | Communicable Disease Control | 2 | 2014 | 72 | 0.570 |
Why?
| | Anti-Retroviral Agents | 2 | 2016 | 208 | 0.560 |
Why?
| | Hepatitis C | 2 | 2015 | 217 | 0.540 |
Why?
| | Patient Identification Systems | 1 | 2015 | 19 | 0.530 |
Why?
| | Antiviral Agents | 3 | 2021 | 654 | 0.520 |
Why?
| | Medical Record Linkage | 1 | 2015 | 53 | 0.510 |
Why?
| | Telemedicine | 2 | 2020 | 664 | 0.500 |
Why?
| | Public-Private Sector Partnerships | 1 | 2014 | 43 | 0.470 |
Why?
| | Vulnerable Populations | 2 | 2018 | 147 | 0.410 |
Why?
| | Hepatitis B Vaccines | 1 | 2012 | 46 | 0.410 |
Why?
| | Hepatitis B | 1 | 2012 | 52 | 0.400 |
Why?
| | Public Health Administration | 1 | 2012 | 78 | 0.400 |
Why?
| | Tuberculosis | 1 | 2014 | 240 | 0.390 |
Why?
| | Health Resources | 1 | 2011 | 132 | 0.370 |
Why?
| | Vaccination | 2 | 2022 | 1222 | 0.350 |
Why?
| | Mass Screening | 6 | 2020 | 1052 | 0.330 |
Why?
| | Immunoglobulin G | 2 | 2022 | 788 | 0.320 |
Why?
| | Hyperkalemia | 1 | 2008 | 24 | 0.310 |
Why?
| | Drug Industry | 1 | 2008 | 104 | 0.290 |
Why?
| | Humans | 37 | 2023 | 118974 | 0.290 |
Why?
| | Health Services Accessibility | 4 | 2020 | 781 | 0.270 |
Why?
| | Interprofessional Relations | 1 | 2008 | 261 | 0.270 |
Why?
| | Community Health Services | 3 | 2016 | 212 | 0.260 |
Why?
| | Health Promotion | 1 | 2011 | 691 | 0.260 |
Why?
| | Electrocardiography | 1 | 2008 | 556 | 0.250 |
Why?
| | AIDS Serodiagnosis | 2 | 2014 | 29 | 0.240 |
Why?
| | Medical Tourism | 1 | 2023 | 10 | 0.230 |
Why?
| | Masks | 1 | 2022 | 48 | 0.210 |
Why?
| | Meningitis | 1 | 2023 | 74 | 0.210 |
Why?
| | North Carolina | 3 | 2018 | 109 | 0.210 |
Why?
| | Adult | 14 | 2021 | 31512 | 0.210 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 97 | 0.200 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2015 | 260 | 0.200 |
Why?
| | Retrospective Studies | 7 | 2022 | 12978 | 0.180 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 664 | 0.180 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 228 | 0.170 |
Why?
| | Teicoplanin | 1 | 2019 | 17 | 0.170 |
Why?
| | Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 1 | 0.170 |
Why?
| | Klebsiella Infections | 1 | 2019 | 23 | 0.170 |
Why?
| | Darunavir | 1 | 2019 | 17 | 0.170 |
Why?
| | beta-Lactamases | 1 | 2019 | 26 | 0.170 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 28 | 0.170 |
Why?
| | Klebsiella pneumoniae | 1 | 2019 | 39 | 0.170 |
Why?
| | Male | 17 | 2021 | 57801 | 0.170 |
Why?
| | Drug Users | 2 | 2020 | 39 | 0.170 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 67 | 0.170 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 64 | 0.160 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 334 | 0.160 |
Why?
| | Patient Dropouts | 1 | 2018 | 66 | 0.160 |
Why?
| | Female | 17 | 2021 | 61565 | 0.160 |
Why?
| | Internship and Residency | 1 | 2008 | 1001 | 0.160 |
Why?
| | HIV Integrase Inhibitors | 1 | 2019 | 60 | 0.160 |
Why?
| | Socioeconomic Factors | 3 | 2018 | 1129 | 0.150 |
Why?
| | Bacteremia | 1 | 2019 | 161 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 667 | 0.150 |
Why?
| | Middle Aged | 10 | 2021 | 27617 | 0.150 |
Why?
| | Aged | 8 | 2021 | 19657 | 0.140 |
Why?
| | Quality Improvement | 2 | 2014 | 963 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2019 | 165 | 0.140 |
Why?
| | Marijuana Use | 1 | 2019 | 157 | 0.140 |
Why?
| | Budgets | 1 | 2015 | 14 | 0.140 |
Why?
| | Referral and Consultation | 3 | 2016 | 648 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 2 | 2014 | 80 | 0.130 |
Why?
| | Biostatistics | 1 | 2015 | 18 | 0.130 |
Why?
| | State Government | 1 | 2015 | 41 | 0.130 |
Why?
| | United States | 6 | 2020 | 12555 | 0.130 |
Why?
| | Confidentiality | 1 | 2015 | 67 | 0.130 |
Why?
| | Population Surveillance | 1 | 2018 | 413 | 0.130 |
Why?
| | Pilot Projects | 1 | 2019 | 1419 | 0.130 |
Why?
| | Drug Costs | 1 | 2015 | 94 | 0.120 |
Why?
| | Tuberculosis, Meningeal | 1 | 2014 | 7 | 0.120 |
Why?
| | Healthcare Financing | 1 | 2014 | 5 | 0.120 |
Why?
| | Young Adult | 7 | 2021 | 10793 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2015 | 149 | 0.120 |
Why?
| | Incidence | 3 | 2021 | 2424 | 0.120 |
Why?
| | Tuberculin Test | 1 | 2014 | 36 | 0.120 |
Why?
| | Adolescent | 7 | 2021 | 18480 | 0.120 |
Why?
| | Interferon-gamma Release Tests | 1 | 2014 | 30 | 0.120 |
Why?
| | Prevalence | 2 | 2020 | 2326 | 0.120 |
Why?
| | Drugs, Generic | 1 | 2013 | 18 | 0.120 |
Why?
| | Bayes Theorem | 1 | 2015 | 344 | 0.120 |
Why?
| | Aged, 80 and over | 5 | 2021 | 6561 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 417 | 0.110 |
Why?
| | Epidemics | 1 | 2014 | 70 | 0.110 |
Why?
| | Colorado | 2 | 2019 | 4196 | 0.110 |
Why?
| | Antitubercular Agents | 1 | 2014 | 163 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2019 | 867 | 0.110 |
Why?
| | Sexually Transmitted Diseases | 1 | 2014 | 155 | 0.100 |
Why?
| | Refugees | 1 | 2012 | 58 | 0.100 |
Why?
| | Sex Work | 1 | 2011 | 17 | 0.100 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 115 | 0.100 |
Why?
| | Prospective Studies | 2 | 2022 | 6471 | 0.100 |
Why?
| | Models, Statistical | 1 | 2015 | 636 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1440 | 0.100 |
Why?
| | Computer Simulation | 1 | 2015 | 922 | 0.100 |
Why?
| | Criminal Law | 1 | 2010 | 26 | 0.090 |
Why?
| | Drug Utilization | 1 | 2011 | 169 | 0.090 |
Why?
| | Homosexuality, Male | 1 | 2011 | 166 | 0.090 |
Why?
| | Sexual Behavior | 1 | 2014 | 437 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1510 | 0.090 |
Why?
| | Insurance, Health | 1 | 2012 | 244 | 0.090 |
Why?
| | Time Factors | 2 | 2020 | 6412 | 0.090 |
Why?
| | Regression Analysis | 1 | 2012 | 983 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1795 | 0.090 |
Why?
| | Texas | 2 | 2020 | 186 | 0.080 |
Why?
| | Patient Compliance | 1 | 2012 | 537 | 0.080 |
Why?
| | Minority Groups | 1 | 2009 | 237 | 0.080 |
Why?
| | Risk Factors | 3 | 2020 | 9000 | 0.070 |
Why?
| | Program Evaluation | 1 | 2011 | 845 | 0.070 |
Why?
| | Brain | 1 | 2019 | 2490 | 0.070 |
Why?
| | Family | 1 | 2010 | 585 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 1865 | 0.060 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 50 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 89 | 0.050 |
Why?
| | Forecasting | 2 | 2014 | 353 | 0.050 |
Why?
| | Assisted Living Facilities | 1 | 2021 | 10 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2021 | 81 | 0.050 |
Why?
| | Curriculum | 1 | 2008 | 910 | 0.050 |
Why?
| | Particulate Matter | 1 | 2023 | 244 | 0.050 |
Why?
| | Drug Approval | 1 | 2021 | 77 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 380 | 0.050 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 122 | 0.040 |
Why?
| | Off-Label Use | 1 | 2019 | 48 | 0.040 |
Why?
| | Oxazines | 1 | 2019 | 25 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 559 | 0.040 |
Why?
| | India | 1 | 2019 | 141 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5116 | 0.040 |
Why?
| | Pyridones | 1 | 2019 | 119 | 0.040 |
Why?
| | Risk-Taking | 1 | 2020 | 319 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2021 | 1687 | 0.040 |
Why?
| | Piperazines | 1 | 2019 | 316 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 965 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 588 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1267 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 598 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1032 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1636 | 0.030 |
Why?
| | Liberia | 1 | 2014 | 6 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 1785 | 0.030 |
Why?
| | Endemic Diseases | 1 | 2014 | 28 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2014 | 129 | 0.030 |
Why?
| | Interinstitutional Relations | 1 | 2014 | 55 | 0.030 |
Why?
| | Long-Term Care | 1 | 2014 | 74 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2674 | 0.030 |
Why?
| | Cost Savings | 1 | 2013 | 77 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 794 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 351 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2012 | 37 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 191 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 9491 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2014 | 208 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 9342 | 0.030 |
Why?
| | Appointments and Schedules | 1 | 2012 | 78 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 254 | 0.030 |
Why?
| | Cost of Illness | 1 | 2014 | 258 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2019 | 3171 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 408 | 0.020 |
Why?
| | Qualitative Research | 1 | 2015 | 953 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2014 | 482 | 0.020 |
Why?
| | Unsafe Sex | 1 | 2009 | 57 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 1901 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5255 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4708 | 0.020 |
Why?
| | Social Support | 1 | 2010 | 542 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 693 | 0.020 |
Why?
| | Child | 2 | 2019 | 19129 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2513 | 0.020 |
Why?
| | Infant | 1 | 2019 | 8293 | 0.020 |
Why?
| | Risk Assessment | 1 | 2014 | 3057 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1185 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2436 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3174 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 4552 | 0.010 |
Why?
|
|
Montague's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|